Correction

The article ‘Preventing diabetic kidney disease progression: an update’ by Jean C. Lu, Elif Ekinci, David O’Neal and Richard J. MacIsaac, which was published in the August 2023 Focus on Cardiometabolic Matters supplement in Medicine Today (pages 15 to 21), contains errors. In the section on Sodium­ glucose cotransporter­-2 inhibitors on page 19, the PBS listings for heart failure for empagliflozin and dapagliflozin are unclear; both are PBS listed for heart failure with reduced ejection fraction, independent of diabetes status. Empagliflozin is stated as not yet being TGA approved. This is incorrect; empagliflozin is TGA approved for heart failure independent of left ventricular ejection fraction. In Table 3 on page 18, the doses of empagliflozin and dapagliflozin are listed as 100 mg. These are incorrect; the doses should be 10 mg. In the same table, empagliflozin and ertugliflozin are spelled incorrectly. As ertugliflozin will no longer be available in Australia, the article text has been updated to reflect this. We apologise for these errors and any confusion they may have caused.
The online version and full­-text PDF of this article are correct at https://medicinetoday.com.au/mt/supplements/
feature­-article/preventing­-diabetic­-kidney­-disease-progression­-update.